EPO Board of Appeal issues communication on BI CRISPR/Cas9 patent hearing

The Board of Appeal of the European Patent Office (EPO) has issued new communication summarising issues that will be discussed at a hearing on whether the EPO erred in its revocation of a patent owned by the Broad Institute.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

Australian biotech sues Grail over multi-cancer blood test

15 September 2026 Grail is facing a patent infringement lawsuit over its Galleri cancer detection test, as Clinical Genomics seeks to enforce its intellectual property while no longer being commercially operational.

Biotech

10x Genomics wins latest round in Parse patent dispute

3 September 2026 Turnaround for 10x after Federal Circuit setback as Delaware jury finds Qiagen-owned Parse infringed three patents covering single-cell sequencing technology.

Biotech

Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win

1 September 2026 Judges dismissed an appeal from MSN Laboratories, which was hoping to show that several patents covering Cabometyx were invalid and would not be infringed by its generic product.

More features

Australian biotech sues Grail over multi-cancer blood test

K&L Gates hires six-partner team of IP and corporate lawyers from Pillsbury

Perfect Pitch: Inside the scheme that gets junior lawyers selling to clients

Built to be bought? What makes companies acquisition-ready

Patent lawyers and judges discuss lofty UPC issues in grand London venue

J&J names two-decade veteran as chief IP counsel

J&J unit win shuts door on Sandoz generic launch

Abbott clinches 18-country PI in glucose monitoring feud

EPO Board of Appeal issues communication on BI CRISPR/Cas9 patent hearing

More on this story

Editor's picks

Editor's picks

More features